Related Experiment Video
Updated: Mar 8, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Human endogenous retroviruses and cancer
María Gonzalez-Cao1, Paola Iduma2, Niki Karachaliou1
1Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona 08028, Spain.
Human endogenous retroviruses (HERVs), remnants of ancient infections, are linked to various cancers. Targeting HERVs offers a promising new avenue for cancer immunotherapy and treatment strategies.
Area of Science:
- Genomics
- Immunology
- Oncology
Background:
- Human endogenous retroviruses (HERVs) constitute approximately 8% of the human genome, originating from ancient retroviral infections.
- Most HERVs are epigenetically silenced or mutated, yet some remain transcriptionally active.
- Aberrant expression of HERVs, particularly HERV-K (HML2) and HERV-K (HML6), is observed in diverse human cancers, including melanoma, breast, renal, ovarian, and germ cell tumors.
Purpose of the Study:
- To explore the potential role of HERVs in human cancer development and progression.
- To investigate the immunogenic properties of HERV-derived proteins and their interaction with the immune system.
- To evaluate the therapeutic potential of targeting HERVs in cancer immunotherapy.
Main Methods:
- Review of existing literature on HERV expression in cancer.
- Analysis of data from animal models demonstrating the oncogenic potential of endogenous retroviruses.
- Examination of HERV-derived peptides' antigenic properties and immune response activation.
Main Results:
- HERV protein expression is a common feature in many human tumors.
- HERV-derived peptides can elicit immune responses, such as activation of CD8+ lymphocytes by HERV-K (HML-6) derived peptides.
- HERVs exhibit dual immunomodulatory effects, including immunosuppression and activation of interferon type I responses.
Conclusions:
- HERVs represent a potential target for cancer therapy due to their association with tumors and immunogenic properties.
- Cellular vaccines or immunomodulatory drugs combined with checkpoint inhibitors targeting HERVs are being explored for cancer treatment.
- Further research is warranted to elucidate the precise mechanisms of HERV involvement in oncogenesis and to optimize HERV-based therapeutic strategies.
More Related Videos
Related Concept Videos
Mechanisms of Retrovirus-induced Cancers
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Non-LTR Retrotransposons
Retroviruses
Retrovirus Life Cycles
Cancer Prevention
Some...

